FLT3 and acute myeloid leukemia: Quizartinib has been studied as a maintenance after allogenic HSCT in a phase 1 study in patients with FLT3-ITD-mutated AML; four patients (31%) stopped quizartinib due to adverse toxicity (NCT01468467) [46].